Symbols / NTRA Stock $229.03 +4.05% Natera, Inc.

Healthcare • Diagnostics & Research • United States • NMS
NTRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Steven Leonard Chapman
Exch · Country NMS · United States
Market Cap 32.80B
Enterprise Value 30.68B
Income -226.32M
Sales 2.50B
FCF (ttm) 136.92M
Book/sh 12.43
Cash/sh 7.60
Employees 6,135
Insider 10d —
IPO Jul 01, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1,099.07
PEG —
P/S 13.12
P/B 18.43
P/C —
EV/EBITDA -114.64
EV/Sales 12.27
Quick Ratio 2.70
Current Ratio 2.96
Debt/Eq 13.53
LT Debt/Eq —
EPS (ttm) -1.63
EPS next Y -0.21
EPS Growth —
Revenue Growth 38.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -9.12%
ROE -15.02%
ROIC —
Gross Margin 65.07%
Oper. Margin -12.39%
Profit Margin -9.05%
Shs Outstand 143.22M
Shs Float 138.92M
Insider Own 3.02%
Instit Own 95.84%
Short Float 2.60%
Short Ratio 2.06
Short Interest 3.61M
52W High 256.36
vs 52W High -10.66%
52W Low 131.81
vs 52W Low 73.75%
Beta 1.54
Impl. Vol. 63.93%
Rel Volume 0.38
Avg Volume 1.40M
Volume 529.30K
Target (mean) $260.05
Tgt Median $265.00
Tgt Low $193.00
Tgt High $300.00
# Analysts 20
Recom Buy
Prev Close $220.11
Price $229.03
Change 4.05%
About

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$260.05
Mean price target
2. Current target
$229.03
Latest analyst target
3. DCF / Fair value
$17.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$229.03
Low
$193.00
High
$300.00
Mean
$260.05

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-05 init Goldman Sachs Buy → Neutral $245
2026-05-11 main BTIG Buy → Buy $250
2026-05-08 main JP Morgan Overweight → Overweight $265
2026-05-08 main Evercore ISI Group Outperform → Outperform $270
2026-05-08 main Wells Fargo Equal-Weight → Equal-Weight $220
2026-04-14 init William Blair — → Outperform —
2026-03-03 main Morgan Stanley Overweight → Overweight $250
2026-02-27 main Wells Fargo Equal-Weight → Equal-Weight $215
2026-02-27 main Evercore ISI Group Outperform → Outperform $260
2026-02-27 main Baird Outperform → Outperform $257
2026-01-07 init Citigroup — → Buy $300
2026-01-05 main Guggenheim Buy → Buy $270
2025-12-22 main Canaccord Genuity Buy → Buy $285
2025-12-15 main Barclays Overweight → Overweight $270
2025-12-15 main JP Morgan Overweight → Overweight $260
2025-12-15 main Wells Fargo Equal-Weight → Equal-Weight $205
2025-12-08 main Canaccord Genuity Buy → Buy $250
2025-12-05 main BTIG Buy → Buy $260
2025-12-02 main Morgan Stanley Overweight → Overweight $265
2025-11-25 main JP Morgan Overweight → Overweight $250
News
RSS: Latest NTRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-05 MARCUS GAIL BOXER Director — 11,000 $22.83 $251,130
2026-06-05 MARCUS GAIL BOXER Director — 11,000 $216.06 $2,389,328
2026-06-04 CHAPMAN STEVEN LEONARD Chief Executive Officer — 41,124 $212.42 $9,089,776
2026-06-01 MOSHKEVICH SOLOMON Officer — 3,000 $217.52 $655,295
2026-06-01 BOTHA ROELOF FREDERICK Director — 78,000 $218.69 $17,184,092
2026-05-29 RUBIN ERIC Director — 2,124 $0.00 $0
2026-05-26 FESKO JOHN President — 1,438 $202.84 $291,684
2026-05-26 MOSHKEVICH SOLOMON Officer — 1,652 $202.84 $335,091
2026-05-13 SHEENA JONATHAN Director — 4,650 $199.43 $959,451
2026-05-05 RABINOWITZ MATTHEW Officer and Director — 2,389 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,306.11
+35.90%
1,696.91
+56.75%
1,082.57
+31.99%
820.22
Operating Revenue
2,306.11
+35.90%
1,696.91
+56.75%
1,082.57
+31.99%
820.22
Cost Of Revenue
812.93
+20.66%
673.75
+14.23%
589.83
+29.28%
456.26
Reconciled Cost Of Revenue
771.17
+19.97%
642.78
+13.62%
565.73
+23.99%
456.26
Gross Profit
1,493.18
+45.94%
1,023.16
+107.65%
492.74
+35.38%
363.97
Operating Expense
1,803.09
+44.77%
1,245.45
+32.64%
938.99
+3.75%
905.01
Research And Development
624.11
+54.43%
404.14
+26.03%
320.68
+1.35%
316.42
Selling General And Administration
1,177.26
+39.93%
841.31
+36.07%
618.31
+5.05%
588.59
Total Expenses
2,616.02
+36.31%
1,919.20
+25.54%
1,528.82
+12.31%
1,361.26
Operating Income
-309.91
-39.41%
-222.29
+50.19%
-446.25
+17.52%
-541.04
Total Operating Income As Reported
-309.91
-39.41%
-222.29
+50.19%
-446.25
+17.52%
-541.04
EBITDA
-220.54
-48.93%
-148.08
+62.78%
-397.80
+23.62%
-520.80
Normalized EBITDA
-220.54
-48.93%
-148.08
+62.78%
-397.80
+23.62%
-520.80
Reconciled Depreciation
43.48
+40.42%
30.97
+28.51%
24.10
+44.28%
16.70
EBIT
-264.02
-47.46%
-179.05
+57.56%
-421.89
+21.51%
-537.50
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Net Income
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Pretax Income
-268.09
-41.30%
-189.73
+56.34%
-434.53
+20.54%
-546.82
Net Non Operating Interest Income Expense
41.82
+28.43%
32.56
+177.96%
11.71
+302.65%
-5.78
Interest Expense Non Operating
4.07
-61.92%
10.69
-15.45%
12.64
+35.62%
9.32
Net Interest Income
41.82
+28.43%
32.56
+177.96%
11.71
+302.65%
-5.78
Interest Expense
4.07
-61.92%
10.69
-15.45%
12.64
+35.62%
9.32
Interest Income Non Operating
45.89
+6.11%
43.25
+77.59%
24.35
+588.33%
3.54
Interest Income
45.89
+6.11%
43.25
+77.59%
24.35
+588.33%
3.54
Other Income Expense
—
—
—
—
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Business
—
—
—
—
Tax Provision
-59.93
-8722.88%
0.69
+156.46%
0.27
-72.29%
0.98
Tax Rate For Calcs
0.00
+6.43%
0.00
+0.00%
0.00
+11566.67%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Net Income From Continuing Operation Net Minority Interest
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Net Income From Continuing And Discontinued Operation
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Net Income Continuous Operations
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Normalized Income
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Net Income Common Stockholders
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Diluted EPS
-1.52
+0.65%
-1.53
+59.52%
-3.78
+32.14%
-5.57
Basic EPS
-1.52
+0.65%
-1.53
+59.52%
-3.78
+32.14%
-5.57
Basic Average Shares
136.72
+9.62%
124.72
+8.45%
115.00
+16.86%
98.41
Diluted Average Shares
136.72
+9.62%
124.72
+8.45%
115.00
+16.86%
98.41
Diluted NI Availto Com Stockholders
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Amortization
1.72
0.00
0.00
—
Amortization Of Intangibles Income Statement
1.72
0.00
0.00
—
Depreciation Amortization Depletion Income Statement
1.72
0.00
0.00
—
Depreciation And Amortization In Income Statement
1.72
0.00
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,398.34
+44.41%
1,660.73
+15.19%
1,441.70
+3.39%
1,394.47
Current Assets
1,496.94
+8.80%
1,375.82
+9.32%
1,258.55
+3.86%
1,211.82
Cash Cash Equivalents And Short Term Investments
1,076.14
+11.14%
968.28
+10.16%
878.98
-2.16%
898.39
Cash And Cash Equivalents
1,076.14
+13.81%
945.59
+47.27%
642.10
+37.76%
466.09
Other Short Term Investments
0.00
-100.00%
22.69
-90.42%
236.88
-45.20%
432.30
Receivables
296.53
-5.61%
314.17
+12.89%
278.29
+13.87%
244.38
Accounts Receivable
296.53
-5.61%
314.17
+12.89%
278.29
+13.87%
244.38
Gross Accounts Receivable
304.55
-5.25%
321.42
+12.87%
284.77
+14.73%
248.22
Allowance For Doubtful Accounts Receivable
-8.02
-10.46%
-7.26
-12.00%
-6.48
-69.22%
-3.83
Inventory
68.44
+52.97%
44.74
+9.78%
40.76
+15.12%
35.41
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
—
0.09
Other Current Assets
55.83
+14.79%
48.63
-19.64%
60.52
+79.95%
33.63
Total Non Current Assets
901.40
+216.38%
284.92
+55.56%
183.15
+0.27%
182.66
Net PPE
349.73
+40.91%
248.19
+47.96%
167.75
+2.08%
164.33
Gross PPE
460.80
+41.09%
326.61
+45.78%
224.04
+12.01%
200.03
Accumulated Depreciation
-111.08
-41.65%
-78.42
-39.30%
-56.29
-57.69%
-35.70
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
196.09
+46.96%
133.43
+34.63%
99.11
+35.71%
73.03
Construction In Progress
94.02
+60.82%
58.46
+98.90%
29.39
+15.85%
25.37
Other Properties
108.54
+25.99%
86.15
+52.38%
56.54
-21.34%
71.87
Leases
62.15
+27.97%
48.57
+24.54%
39.00
+31.10%
29.75
Goodwill And Other Intangible Assets
514.78
+4608.52%
10.93
—
—
Goodwill
141.07
0.00
—
—
Other Intangible Assets
373.71
+3318.21%
10.93
—
—
Other Non Current Assets
36.90
+43.08%
25.79
+67.42%
15.40
-15.97%
18.33
Total Liabilities Net Minority Interest
685.93
+47.41%
465.31
-31.20%
676.37
-1.79%
688.73
Current Liabilities
441.23
+28.25%
344.05
+11.97%
307.27
-1.04%
310.50
Payables And Accrued Expenses
218.31
+36.13%
160.37
+23.80%
129.54
-12.93%
148.78
Payables
63.10
+60.41%
39.34
+110.04%
18.73
-47.19%
35.47
Accounts Payable
33.16
-5.06%
34.92
+132.84%
15.00
-51.85%
31.15
Other Payable
21.58
—
—
—
Current Accrued Expenses
155.21
+28.23%
121.03
+9.23%
110.81
-2.21%
113.31
Pensionand Other Post Retirement Benefit Plans Current
92.60
+49.09%
62.11
+35.45%
45.86
+4.20%
44.01
Total Tax Payable
8.37
+89.42%
4.42
+18.36%
3.73
-13.61%
4.32
Income Tax Payable
—
—
—
4.32
Current Debt And Capital Lease Obligation
95.90
+5.94%
90.53
-1.62%
92.02
+4.58%
87.99
Current Debt
80.32
-0.05%
80.36
-0.05%
80.40
+0.06%
80.35
Other Current Borrowings
—
—
—
80.35
Current Capital Lease Obligation
15.58
+53.24%
10.17
-12.50%
11.62
+52.13%
7.64
Current Deferred Liabilities
24.91
+26.09%
19.75
+18.91%
16.61
+54.14%
10.78
Current Deferred Revenue
24.91
+26.09%
19.75
+18.91%
16.61
+54.14%
10.78
Total Non Current Liabilities Net Minority Interest
244.70
+101.78%
121.27
-67.14%
369.10
-2.41%
378.23
Long Term Debt And Capital Lease Obligation
118.47
+22.66%
96.59
-72.40%
349.97
-2.31%
358.23
Long Term Debt
—
—
282.94
+0.46%
281.65
Long Term Capital Lease Obligation
118.47
+22.66%
96.59
+44.11%
67.03
-12.47%
76.58
Tradeand Other Payables Non Current
96.78
0.00
—
—
Non Current Deferred Liabilities
17.76
+5.49%
16.84
-11.97%
19.13
-4.36%
20.00
Non Current Deferred Revenue
17.06
+1.33%
16.84
-11.97%
19.13
-4.36%
20.00
Non Current Deferred Taxes Liabilities
0.70
0.00
—
—
Other Non Current Liabilities
11.69
+48.99%
7.84
—
—
Stockholders Equity
1,712.41
+43.25%
1,195.42
+56.20%
765.33
+8.44%
705.74
Common Stock Equity
1,712.41
+43.25%
1,195.42
+56.20%
765.33
+8.44%
705.74
Capital Stock
0.01
+16.67%
0.01
+9.09%
0.01
+0.00%
0.01
Common Stock
0.01
+16.67%
0.01
+9.09%
0.01
+0.00%
0.01
Share Issued
139.69
+5.31%
132.65
+10.93%
119.58
+7.48%
111.25
Ordinary Shares Number
139.69
+5.31%
132.65
+10.93%
119.58
+7.48%
111.25
Additional Paid In Capital
4,488.68
+19.27%
3,763.61
+19.64%
3,145.84
+18.05%
2,664.73
Retained Earnings
-2,776.02
-8.11%
-2,567.86
-8.01%
-2,377.44
-22.38%
-1,942.63
Gains Losses Not Affecting Retained Earnings
-0.26
+25.00%
-0.34
+88.85%
-3.08
+81.15%
-16.36
Other Equity Adjustments
-0.26
+25.00%
-0.34
+88.85%
-3.08
+81.15%
-16.36
Total Equity Gross Minority Interest
1,712.41
+43.25%
1,195.42
+56.20%
765.33
+8.44%
705.74
Total Capitalization
1,712.41
+43.25%
1,195.42
+14.04%
1,048.27
+6.17%
987.40
Working Capital
1,055.71
+2.32%
1,031.78
+8.46%
951.27
+5.54%
901.32
Invested Capital
1,792.74
+40.52%
1,275.78
+13.03%
1,128.67
+5.71%
1,067.75
Total Debt
214.38
+14.57%
187.12
-57.66%
441.99
-0.95%
446.22
Net Debt
—
—
—
—
Capital Lease Obligations
134.05
+25.57%
106.76
+35.74%
78.65
-6.61%
84.22
Net Tangible Assets
1,197.63
+1.11%
1,184.49
+54.77%
765.33
+8.44%
705.74
Tangible Book Value
1,197.63
+1.11%
1,184.49
+54.77%
765.33
+8.44%
705.74
Current Provisions
9.51
-15.69%
11.28
-51.49%
23.25
+22.68%
18.95
Interest Payable
—
0.00
-100.00%
1.08
+0.00%
1.08
Line Of Credit
80.32
-0.05%
80.36
-0.05%
80.40
+0.06%
80.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
215.30
+58.70%
135.66
+154.93%
-246.96
+42.77%
-431.50
Cash Flow From Continuing Operating Activities
215.30
+58.70%
135.66
+154.93%
-246.96
+42.77%
-431.50
Net Income From Continuing Operations
-208.16
-9.31%
-190.43
+56.20%
-434.80
+20.63%
-547.80
Depreciation Amortization Depletion
43.48
+40.42%
30.97
+28.51%
24.10
+44.28%
16.70
Depreciation
41.76
+34.86%
30.97
+28.51%
24.10
—
Amortization Cash Flow
1.72
0.00
0.00
—
Depreciation And Amortization
43.48
+40.42%
30.97
+28.51%
24.10
+44.28%
16.70
Amortization Of Intangibles
1.72
0.00
0.00
—
Other Non Cash Items
18.71
+0.03%
18.71
+0.90%
18.54
-24.69%
24.62
Stock Based Compensation
354.40
+29.14%
274.43
+43.07%
191.81
+25.87%
152.38
Provisionand Write Offof Assets
—
—
—
1.77
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
-3.22
-796.54%
0.46
+74.34%
0.27
-70.69%
0.90
Gain Loss On Investment Securities
-3.23
—
—
0.91
Unrealized Gain Loss On Investment Securities
—
—
—
-0.00
Net Foreign Currency Exchange Gain Loss
0.02
-96.32%
0.46
+74.34%
0.27
+13350.00%
-0.00
Change In Working Capital
10.04
+369.17%
2.14
+104.46%
-47.95
+42.33%
-83.15
Change In Receivables
20.75
+157.84%
-35.88
-5.82%
-33.90
+72.28%
-122.31
Changes In Account Receivables
20.75
+157.84%
-35.88
-5.82%
-33.90
+72.28%
-122.31
Change In Inventory
-20.87
-423.74%
-3.98
+25.56%
-5.35
+37.00%
-8.50
Change In Prepaid Assets
-8.63
-179.89%
10.81
+141.45%
-26.07
-2069.05%
-1.20
Change In Payables And Accrued Expense
92.37
+95.85%
47.16
+185.69%
16.51
-70.62%
56.18
Change In Accrued Expense
91.61
+169.83%
33.95
+6.21%
31.97
-36.97%
50.72
Change In Payable
0.75
-94.30%
13.21
+185.46%
-15.46
-383.01%
5.46
Change In Account Payable
0.75
-94.30%
13.21
+185.46%
-15.46
-383.01%
5.46
Change In Other Working Capital
-58.05
-6913.03%
0.85
-82.83%
4.96
+141.34%
2.06
Change In Other Current Assets
4.23
0.00
-100.00%
8.35
+1243.09%
0.62
Change In Other Current Liabilities
-19.75
-17.43%
-16.82
-35.11%
-12.45
-24.49%
-10.00
Investing Cash Flow
-132.21
-196.07%
137.62
-18.32%
168.50
-48.99%
330.34
Cash Flow From Continuing Investing Activities
-132.21
-196.07%
137.62
-18.32%
168.50
-48.99%
330.34
Net PPE Purchase And Sale
-106.19
-59.87%
-66.42
-69.45%
-39.20
+17.82%
-47.70
Purchase Of PPE
-106.19
-59.87%
-66.42
-69.45%
-39.20
+17.82%
-47.70
Capital Expenditure
-139.19
-80.96%
-76.92
-96.22%
-39.20
+17.82%
-47.70
Net Investment Purchase And Sale
23.00
-89.28%
214.54
+3.30%
207.70
-45.06%
378.04
Purchase Of Investment
0.00
+100.00%
-124.68
-26.83%
-98.30
-13.06%
-86.95
Sale Of Investment
23.00
-93.22%
339.22
+10.86%
306.00
-34.19%
464.98
Net Business Purchase And Sale
-16.02
0.00
0.00
—
Purchase Of Business
-16.02
0.00
0.00
—
Gain Loss On Sale Of Business
—
—
—
—
Net Intangibles Purchase And Sale
-33.00
-214.44%
-10.49
0.00
0.00
Purchase Of Intangibles
-33.00
-214.44%
-10.49
0.00
0.00
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
47.46
+57.13%
30.20
-88.13%
254.46
-47.28%
482.64
Cash Flow From Continuing Financing Activities
47.46
+57.13%
30.20
-88.13%
254.46
-47.28%
482.64
Net Issuance Payments Of Debt
0.00
+100.00%
-0.08
0.00
-100.00%
30.00
Issuance Of Debt
—
0.00
0.00
-100.00%
30.00
Repayment Of Debt
0.00
+100.00%
-0.08
0.00
0.00
Long Term Debt Issuance
—
0.00
0.00
-100.00%
30.00
Long Term Debt Payments
0.00
+100.00%
-0.08
0.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-0.08
0.00
-100.00%
30.00
Short Term Debt Issuance
—
—
0.00
-100.00%
30.00
Net Short Term Debt Issuance
—
—
0.00
-100.00%
30.00
Net Common Stock Issuance
0.00
0.00
-100.00%
235.44
-45.65%
433.19
Proceeds From Stock Option Exercised
47.57
+57.08%
30.29
+59.23%
19.02
-2.20%
19.45
Net Other Financing Charges
-0.11
—
—
—
Changes In Cash
130.55
-56.98%
303.49
+72.43%
176.00
-53.86%
381.48
Beginning Cash Position
945.59
+47.27%
642.10
+37.76%
466.09
+450.84%
84.61
End Cash Position
1,076.14
+13.81%
945.59
+47.27%
642.10
+37.76%
466.09
Free Cash Flow
76.11
+29.56%
58.75
+120.53%
-286.15
+40.28%
-479.20
Interest Paid Supplemental Data
4.07
-48.47%
7.90
-30.40%
11.35
+40.77%
8.06
Income Tax Paid Supplemental Data
0.50
-61.82%
1.31
+343.05%
0.29
-46.27%
0.55
Amortization Of Securities
0.03
+105.18%
-0.62
-156.85%
1.09
-77.53%
4.84
Common Stock Issuance
0.00
0.00
-100.00%
235.44
-45.65%
433.19
Issuance Of Capital Stock
0.00
0.00
-100.00%
235.44
-45.65%
433.19
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category